INTRODUCTION 1
Cancer formation is the result of an accumulation of numerous, ongoing genetic and 2 epigenetic changes, and it is this complexity that allows cancer cells to escape 3 monotherapy. Consequently, much effort has gone into developing a single-molecule 4 with multiple functions as an anti-cancer strategy. SiRNA-driven RNA interference 5 has received positive attention in this regard [1] [2] [3] , as in addition to anti-tumor effects 6 through oncogene silencing, there is a growing body of evidence suggesting that 7 innate immune activation can increase the anti-tumor effects of siRNA 4, 5 . Hence, 8 this approach offers great promise as an anti-cancer therapy, either alone or as a co-9
treatment. 10 11
SiRNAs were originally thought to escape innate immune recruitment, however they 12 are now known to be potent activators of several innate immune sensors including 13 TLR7. In both human and mouse, TLR7 senses both siRNAs and single-stranded 14
RNAs in a sequence-specific manner 6-8 , which leads to the production of several 15 pro-inflammatory cytokines, such as IFN 6, 8 . IFN has anti-proliferative abilities and 16 is widely used in the treatment of a range of cancers including renal cell carcinoma, 17 melanoma and a range of hemopoetic malignancies (as reviewed in Mitchell SiRNA itself has potent anti-tumor activity due to the direct down-modulation of 2 target genes such as HPV E6 and E7 1, 17, 18 and such control of tumors is known to 3 occur in the absence of measurable innate immune activation 3 . Due to the plasticity 4 of cancer cells, it is thought that developing 'bifunctional' siRNAs that can both 5 silence target genes and activate innate immune responses would elicit a more 6 potent anti-cancer response which is less susceptible to therapeutic escape. 7
Evidence of siRNA bifunctionality yielding an improved anti-tumor effect was recently 8 demonstrated by Poeck et al 4 , where innate immune activation relied on the 9 recruitment of RIG-I by 5'-triphosphate-siRNA. Using a slightly different approach, 10
Kortylewski et al have shown that combining STAT3 siRNA with CpG oligo DNA, a 11 potent TLR9 agonist, yielded potent anti-tumor effects via activation of tumor-12 resident macrophages and restoration of normal immune function 5 . Despite this 13 progress, anti-tumor strategies using siRNA to both silence oncogenes and recruit 14 TLR7 are still ill-defined. To date there is no knowledge of whether siRNA 15 bifunctionality could be exploited to treat HPV-driven tumors. 16
17
In this work we investigated the use of unmodified siRNAs in combination with innate 18 immune recruitment for the treatment of tumors driven by HPV where cancer survival 19 is entirely reliant on the expression of E6/E7 oncogenes 19 . It has been previously 20
shown that the loss of E6/E7 expression in various cervical cancer cell lines via RNAi 21 is a potent inducer of apoptosis in vitro 17, 18, 20, 21 . We studied the contribution of 22 immunostimulatory properties of siRNAs on E6/E7 driven tumor development. By 23
showing that siRNA-induced immunostimulation via TLR7 has a significant anti-24 tumor effect, even in the absence of specific gene silencing, our in vivo findings 25 been reported that ssRNAs/siRNAs delivered using DOTAP-based agents relies 1 exclusively on TLR7 in mouse cells, due to lack of mouse TLR8 response to RNA 2 agonists 6, 8 . We observed that while IDT-4 maintained highest immunostimulation in 3 levels of TNF , 2'OMe modification of IDT-4 ablated TLR-activating ability, giving 4 background levels of TNF (Figure 2a) . To confirm TLR7 recruitment by these 5 siRNAs, we measured the levels of TNF in immortalized TLR7
-/-and TLR7 +/+ BMMs 6 28 . In TLR7 -/-cells, IDT-4-driven cytokine production levels were similar to those 7 obtained with IDT-4m7 (Figure 2b ). However, immortalized TLR7 +/+ BMMs 8 maintained similar immunostimulation profiles as seen in mouse BMMs (Figure 2c) , 9
with IDT-4 producing a greater immunostimulatory effect than IDT-4m7. In order to 10 test whether modification altered RNAi ability, we then quantified the mRNA 11 knockdown level of IDT-4m7 using qRT-PCR (Figure 2d ) following transfection of 12 TC-1 cells as described above. We observed that IDT-4m7 retained RNAi ability and 13 was able to significantly knockdown HPV16 E6/E7, albeit with a 13% reduction of 14 efficacy as compared to IDT-4 ( Figure 2d) . 15
16

Induction of IFN is transient in vivo 17
To confirm whether the activation of TLR7 by D-siRNAs observed in vitro would also 18 occur in vivo, we measured IFN levels in serum collected from mice at 4 We also tested BP1 Mod2 siRNA, previously shown to be a strong IFN inducer in 2 vivo 7 . Although BP1 Mod2 induced IFN to lower levels compared to IDT-4, IFN 3 was still detectable at 24 hours post-injection. The scrambled siRNA control also 4 induced a low level of IFN at 4 and 8 hours, but at significantly reduced levels 5 compared to all other siRNAs. Induction of IFN was not detectable at 48 hours post-6 injection in all siRNAs, showing that IFN induction in vivo by siRNAs was not 7 sustained. 
Pre-treatment with siRNAs impacts tumor formation 25
Having established the silencing efficacy and innate immune potential of IDT-4, we 1 next tested whether this siRNA could impact tumor formation. IDT-12 was included in 2 this study as this D-siRNA has similar E6/E7 knockdown ability to IDT-4 but lower 3 immunostimulatory potency (Figure 1c and data not shown), while scrambled D-4 siRNA was used as a negative control. TC-1 cells stably expressing luciferase (TC-5 1-luci) were treated with 40nM siRNAs delivered via liposomes for 4 hours at which 6 time 1×10 6 cells were subcutaneously injected into each C57BL/6 mouse. Tumors 7 were allowed to form over 14 days, and caliper measurements were carried out 8 every two days from the day tumors could be detected from palpation, until the end 9 of the experiment. On day 14, mice were injected with D-luciferin and the tumors 10 were imaged by luminescence. Tumors were also collected and weighed at day 14. To test for anti-tumor activity by systemically delivered siRNAs, tumors were 25 established in mice by subcutaneous injection of 1×10 6 TC-1 cells on day 0 followed 1 by systemic RNAi treatment of 40µg D-siRNA per dose (~2mg/kg) via I.V. tail vein 2 injection on days 5, 8, and 12. This protocol was performed in parallel to our recently 3 published studies on liposomal delivery in vivo, which showed substantial siRNA 4 uptake by target cells using this delivery method 34 . To investigate the contribution of 5 innate immune activation in the anti-tumor effects, we compared the effects of IDT-4 6 versus IDT-4m7, which had shown no immunostimulatory effect (Figure 5a, b) . 7
Scrambled-m7 was used as a negative control as it had neither silencing nor 8 immunostimulatory effects (Figure 2a an anti-tumoral effect, we tested two siRNAs that are non-specific to HPV and which 25 vary widely in their immunostimulatory activity. These were BP1Mod2, which is 1 strongly immunostimulatory, and gal 924 which has no immunostimulatory activity 
MyD88
-/-mice. These preliminary results suggest further the important contribution of 20 immunostimulation in the anti-tumor effects previously seen with these sequences. 21
Overall, our data highlights the anti-tumor ability of siRNA-induced 22 immunostimulation via TLR7, even in the absence of specific gene-silencing. . Here we show that activation of the innate immune response by siRNAs 5 has significant anti-tumor effects against HPV-driven tumors, even in the absence of 6 a specific gene target. Although the most prolonged siRNA-induced 7 immunostimulation in our system reached 24 hours, impact on tumor growth was 8 observed up to 3 days following the last siRNA injection (i.e. on day 10). On the 9 other hand, oncogene-specific siRNA with immunostimulatory ability gave long term 10 anti-tumor control with anti-tumor effect observed on day 10 and sustained on day 11
14. The responses we observed are specific to HPV-driven tumors and one would 12 expect different cancers to exhibit varying sensitivity to such therapy. This is 13 . However, this motif was absent in other highly active siRNAs 4 (e.g. IDT-5, -6, -8 and -14). We did note that high immunostimulation in these D-5 siRNAs appeared to be associated with a UXUCU motif starting at position 9 or 10 6 downstream from the 5' end of the antisense strand, with IDT-4 having both UXUCU 7 and UGUGU motifs (Supplementary Figure S3) . 8 9
Our study also demonstrates that the immunostimulatory profiles of our D-siRNAs 10 are similar in vivo to their initial in vitro profiles with IDT-4 consistently demonstrating 11 the highest level of immunostimulation in both settings. We also observed TLR7 12 specificity pertaining to siRNA-induced immunostimulation. IDT-4 induced 13 immunostimulation was concurrent with the activation of DCs and NK cells. 14 Furthermore, we showed that in vivo induction of IFN by immunostimulatory siRNAs 15 is transient, lasting 4 to 8 hours. Although we have established that 16 immunostimulation by our D-siRNAs is sequence-dependent, we also observed that 17 addition of methyl groups to the antisense strand of these siRNAs abolishes their in 18 vivo immunostimulatory ability, thus supporting results previously published 3, 27, 37 . 19
However, the RNAi ability by these modified siRNAs was retained, allowing us to 20 directly compare the effects of TLR7 activation on tumor reduction. 21
22
SiRNAs delivered systemically will target not only to tumor cells, but also to cells of 23 the liver, lung, and spleen -the primary sites of liposomal deposition 29, 34 , hence 24 activating immune cells such as macrophages, dendritic cells and monocytes, 25 benefiting anti-tumor activity. To address the activation of these immune cells by 1 siRNAs, we treated established tumors in mice with systemically-delivered siRNAs 2 on days 5, 8, and 12, and observed tumor sizes on days 10 and 14. We observed 3 that siRNA with both RNAi and immunostimulatory abilities gave persistent anti-4 tumor effects. We suggest that TLR7 activation played a significant role in this tumor 5 reduction, as loss of TLR7 activity via siRNA sequence modification or ablation of 6 myD88 pathway impaired this siRNA-mediated tumor reduction. Further, 7 immunostimulation alone had potent anti-tumor activity as demonstrated by the 8 activity of BP1 Mod2 on day 10; an effect not seen in MyD88
-/-mice treated with this 9 immunostimulatory siRNA. We also found these non-specific immunostimulatory 10 effects by BP1 Mod2 to be transient as tumor sizes returned to control levels by day 11
14. This data point suggests that gene silencing-independent anti-tumor effects 12 through potential TLR7 activation to be transient. 
METHODS 13
Cell lines 14
Caski cells line was obtained from the American Type Culture Collection (ATCC). Protein extraction was performed on cells 24 hours after transfection. Protein was 6 extracted using radioimmunoprecipitation assay (RIPA) lysis buffer (150mM NaCl, 7 0.1% SDS, 0.5% sodium deoxycholate, 1% Nonidet P-40, and 50mM Tris, pH 8.0) 8 with the addition of 2mM phenylmethlsulfonyl fluoride (PMSF) and 1µL/mL Protease 9
Inhibitor Cocktail (PIC) (Sigma, Sydney, Australia). Lysis buffer was freshly prepared 10 and added to transfected cells in 6-well plates (200µL/well), and incubated for 10 11 minutes on ice. Protein concentration was determined using protein assay kit (Bio-12
Rad, Hercules, CA) with the appropriate standards. Cell extracts were boiled for 10 13 Zealand) according to protocol. cDNA synthesis was performed using Omniscript 25
Reverse Transcriptase kit (Qiagen, Hilden, Germany) according to manufacturer's 1 protocol. Real-time PCR was carried out using SYBR® Green PCR Master Mix (ABI, 2 Warrington, UK) according to manufacturer's protocol with primers as described in 3
Supplementary Table 3 . 4
The PCR was carried out on Rotorgene 6000 (Corbett) as follows: initial denaturing 5 at 95°C for 10 minutes, 40 cycles of 95°C for 10 seconds (denature), 60°C for 15 6 seconds (anneal), and 72°C for 20 seconds (extension), and melt conditions at 75°C 7 to 95°C rising at 1°C each step. Data was analysed using the Rotor-Gene 6000 8 series software. 9 10
Detection of cytokines 11
Human IFN in culture supernatants was quantified by sandwich ELISA using 0.5 12 g/ml mouse monoclonal (PBL Biomedical) and rabbit polyclonal antibodies (PBL 13 Biomedical) respectively. A goat anti-rabbit HRP-conjugated antibody (Pierce) at 14 0.8 g/ml was used for detection. Mouse TNF was measured using the BD OptEIA 15 ELISA set (BD Biosciences, North Ryde, Australia). In both IFN and TNF ELISAs, 16 TMB substrate (Sigma, Castle Hill, NSW, Australia) was used for quantification of the 17 cytokines on the Fluostar OPTIMA plate-reader. France). Flow cytometry data was analysed using Flowjo7.6 (Flowjo, Ashland, OR). 16
17
Cationic liposomes 18
For transfection of TC-1/TC-1-luci cells, cationic liposomes were prepared using 19 dioleoyl trimethylammonium propane (DOTAP) (Sigma, St Louis, MO) and dioleoyl 20 phosphatidylethanolamine (DOPE) (Northern Lipids, Vancouver, Canada) at a 1:1 21 molar ratio as previously described 45 , resulting in a dried, thin lipid film. The lipid film 22 was hydrated with sterile 5% dextrose solution to give a final concentration of 23 2.5x10 -6 mole DOTAP/mL. The resulting liposomes was left to stabilize at room 24 temperature for two hours followed by size reduction of the multilamellar liposomes 25 performed according to the procedure described in Wu et al 29 . The resulting small 1 unilamellar liposomes were subsequently complexed with siRNA at Nitrogen to 2 Phosphate (N:P) ratios of 4:1 for transfection as described above. Table  2 1: Sequences of siRNAs used in this study. 
